Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma

Reuters

2025/10/31

Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma

Transcenta Holding Limited has announced that its partner, Inhibrx Biosciences, Inc., has reported positive topline results from the registrational ChonDRAgon Phase 2 study of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma. The study, which included 206 patients, investigated ozekibart as a single agent versus placebo. Based on these results, Inhibrx plans to submit a Biologics License Application (BLA) in 2026. Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, with Fast Track and orphan drug designations from the U.S. FDA for chondrosarcoma. Inhibrx is also evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with early signals supporting further exploration in these tumor types.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579310166"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579310166\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579310166?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 06:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579310166","market":"fut","top_or_hot":-1,"title":"Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Transcenta Holding Limited has announced that its partner, <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a>, Inc., has reported positive topline results from the registrational ChonDRAgon Phase 2 study of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma. The study, which included 206 patients, investigated ozekibart as a single agent versus placebo. Based on these results, Inhibrx plans to submit a Biologics License Application (BLA) in 2026. Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, with <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and orphan drug designations from the U.S. FDA for chondrosarcoma. Inhibrx is also evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with early signals supporting further exploration in these tumor types.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTranscenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-31 06:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Transcenta Holding Limited has announced that its partner, <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a>, Inc., has reported positive topline results from the registrational ChonDRAgon Phase 2 study of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma. The study, which included 206 patients, investigated ozekibart as a single agent versus placebo. Based on these results, Inhibrx plans to submit a Biologics License Application (BLA) in 2026. Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, with <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and orphan drug designations from the U.S. FDA for chondrosarcoma. Inhibrx is also evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with early signals supporting further exploration in these tumor types.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INBX","symbol_name":"Inhibrx Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL9hyr32:1","article_id":"2579310166","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579310166","pubTimestamp":1761864283,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Transcenta Holding Limited has announced that its partner, Inhibrx Biosciences, Inc., has reported positive topline results from the registrational ChonDRAgon Phase 2 study of ozekibart  in patients with advanced or metastatic, unresectable chondrosarcoma. The study, which included 206 patients, investigated ozekibart as a single agent versus placebo. Based on these results, Inhibrx plans to submit a Biologics License Application  in 2026. Ozekibart is a precision-engineered, tetravalent death receptor 5  agonist antibody, with Fast Track and orphan drug designations from the U.S. FDA for chondrosarcoma. Inhibrx is also evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with early signals supporting further exploration in these tumor types.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INBX":"Inhibrx Biosciences","BK1161":"生物科技","BK4139":"生物科技","06628":"创胜集团-B"},"translate_title":"Transcenta报告Ozekibart治疗软骨肉瘤的积极2期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":0.9,"06628":0.9},"content_text":"Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma\n    \n\n        Transcenta Holding Limited has announced that its partner, Inhibrx Biosciences, Inc., has reported positive topline results from the registrational ChonDRAgon Phase 2 study of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma. The study, which included 206 patients, investigated ozekibart as a single agent versus placebo. Based on these results, Inhibrx plans to submit a Biologics License Application (BLA) in 2026. Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, with Fast Track and orphan drug designations from the U.S. FDA for chondrosarcoma. Inhibrx is also evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with early signals supporting further exploration in these tumor types.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}